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ABSTRACT 
 In my thesis, I study whether a patient experiencing longer wait times in the 
emergency department (ED) is more or less likely to receive a medication, a 
non-prescription drug, or intravenous therapy (IV). Using survey data from the National 
Center for Health Statistics (NCHS), I analyze a sample of 98,451 ED visits from 2012 to 
2016. My key variable is wait time, measured as a series of indicator variables for each 
quartile of the wait time distribution. My three outcome variables are: (1) indicator for 
receiving a medication, (2) indicator for receiving a non-prescription drug, and (3) 
indicator for whether an IV was given. I use four models for all three outcomes by 
including the following control variables in my analysis: (1) demographic information of 
the patients such as age, sex and race, (2) payment method, and (3) clinical characteristics 
such as pain scale and symptoms. I also include dummy variables for each respective 
year to capture any macro-trends. I find that patients in the 4th quartile of wait time have 
lower odds of receiving a medication, patients in the 3rd quartile have lower odds of 
receiving a non-prescription drug, and patients in the 2nd, 3rd, and 4th quartile have 
lower odds of being given an IV. Many control variables are also correlated with my 
outcomes, such as age, sex, race, pain scale, and symptoms. My results have implications 
for optimal staffing of triage units in hospitals, advancing work flows efficiencies, and 
cutting waste. 
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A. RESEARCH TOPIC   
My research studies the correlation between wait times and the likelihood of 
providers prescribing medications and IV to emergency department (ED) patients. I 
accomplish this by using survey data from the National Center for Health Statistics (NCHS) 
and analyzing a sample of 98,451 individuals from 2012 to 2016. I use four models to find 
any association my key indicator variable and control variables have on three separate 
outcome variables.  
I accomplish my research by analyzing three outcome variables against the same 
four models. My outcome variables include: (1) Outcome #1 indicator for any medication 
received by a patient; (2) Outcome #2 indicator for a non-prescription drug being received 
by a patient; (3) Outcome #3 indicator for an IV being given to a patient. These outcome 
variables are discussed in detail in Chapter III. My control variables include demographic 
information, payment method, and clinical characteristics. 
B. BACKGROUND 
The baby boomer generation is currently entering retirement years, meaning this 
generation has reached Medicare eligibility in the U.S. By 2030, 20% of the U.S. 
Population will be 65 or older (Silverman, 2018). Additionally, the baby boomer generation 
average five or more medications (Brownlee et al., 2019). Due to this, healthcare demand 
in the U.S. is growing, but waste in the healthcare system has also grown. At the same time, 
more patients are utilizing EDs as their primary source of care at higher rates. For example, 
a 2011 study showed that ED visits increased 45% from 1998 to 2009 (He et al., 2011). In 
a separate study by the University of Maryland School of Medicine patients are observed 
to be receiving 50% of their medical care in the U.S. by EDs (2017). These facts are 
alarming and indicate an increased and growing demand from patients to get their medical 
needs met by an ED. 
In addition to the growing demand placed on EDs, there is also a growing deficit in 
physicians. Current projections expect physician shortages to reach 40,800 to 104,900 by 
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2030 (Feldstein, 2019). This shortage becomes most evident when patients begin 
recognizing longer than average wait times. Current wait times to schedule an appointment 
to see a physician range across the country. For example, in Dallas patients wait 12 days 
to see their physician, but in Boston the wait time is 45 days (Feldstein, 2019). These data 
points (physician shortage and varying wait times) imply the healthcare industry is not 
operating at peak or optimal efficiency levels. In fact, current waste in the healthcare 
system is estimated to be $760 to $935 billion/year (Shrank et al., 2019). These findings 
give credence to research projects like mine that are capable of identifying areas of patient 
care that may be improved in a coordinated effort to operate more efficiently and 
effectively. 
Based on these facts, there is an expected increase in the future with respect to 
demand on ED providers and their staffs. This increased demand requires EDs to be 
proactive in finding measures to becoming more efficient in order to meet future demands. 
In my thesis I analyze whether increased demand of the ED staff (proxied by emergency 
department wait time) is associated with changes in medication prescription patterns. Such 
analysis can potentially offer insights for improved resource management.  
Due to the growing opioid crisis in the United States, the majority of studies relating 
to my analysis are opioid-specific. These studies do aid in the literature review process for 
my work, and do provide interesting data points for trends that exist in the prescribing 
behaviors of opioids, but not much exists on my three outcome variables. My hope is that 
the results from my study warrant further research in order to better understand how 
variables such as wait time and clinical characteristics such as whether a patient arrived by 
an ambulance affect the probability of a patient being prescribed a medication.  
In the current U.S. healthcare system there is a trend occurring where more patients 
are seeking to receive their medical care needs from EDs. Due to this trend, my thesis starts 
by analyzing the likelihood of a patient receiving a medication while visiting an ED. In an 
article by Zeis (2016) a survey was sent to ED staffs to discover how they limit what they 
call “avoidable” visits for patients. The number two response (56% of respondents) is for 
EDs to limit prescriptions for opioids, and the number seven response (36% of respondents) 
included a way of tracking patients that seek opioid drugs (Zeis, 2016). These types of 
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responses tell me that patients (in this case patients seeking opioids) use EDs to get their 
prescription drug needs met. My thesis looks at variables that have a relationship with a 
drug being prescribed for the same purpose, to discover if there are variables that help 
healthcare professionals understand various methods or ways to minimize these 
“avoidable” visits.  
Another takeaway from Zeis (2016) is that 15% of respondents claimed that 
inadequate ED staff is a cause of inefficiencies. These shortages create bottlenecks that 
results in EDs becoming overworked and possibly unable to meet all of the demands of 
patients. I believe the results from my analysis offer tangible takeaways for healthcare 
professionals to use in order to counter these potential bottlenecks and/or modify workflow 
processes in their manpower programs. This is accomplished by utilizing my findings and 
tailoring programs to their localized data. 
C. HOW CAN MY RESEARCH BENEFIT THE MILITARY? 
The military system currently provides a significant healthcare benefits package to 
Active Duty, Dependents, and Retirees. Retired military personnel live longer than 
previous generations which turns into greater demand on the military health system overall. 
I previously discussed civilian specific growth trends, and in my analysis I assume the 
military health system will see the same growth in patient demand. The goal of my thesis 
is to identify variables that directly affect all medical providers, both inside and outside of 
the military health system. I aim to better understand relevant variables capable of helping 
providers focus their efforts, and bring these efficiencies and future initiatives to fruition.  
The findings in my thesis have the ability to benefit military healthcare 
professionals in multiple ways. For example, I believe these findings can support 
healthcare professionals in identifying possible efficiencies in triaging patients. Also, my 
results offer insight into demographic variables that can be used in a localized manner to 
project and plan manpower needs, based on local demographics for a healthcare facility. 
For example, in my findings I identify unique characteristics for age, sex, race, and 
ethnicity all of which aid healthcare professionals to better understand their patients and 
plan for their needs. This can include creative solutions to meet patient needs such as 
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implementing alternative methods of providing care to these patients (e.g., e-visit vs face-
to-face). Lastly, the macro-trends evident in my findings will aid in projecting future 
demand on the military health system. 
D. RESEARCH OBJECTIVE 
In my analysis I study the association between wait times and the likelihood of a 
patient receiving a medication, receiving a non-prescription drug, and an IV being given. 
These three outcomes are analyzed against my key indicator variable wait time, controlling 
for demographic information, payment method, and clinical characteristics of a patient. 
Finally, I also include year fixed effects in my regressions to control for any macro-trends 
in prescription behaviors in EDs.  
In my thesis, I analyze three medication outcomes: (1) Outcome #1 whether a 
patient received medication of any kind during the ED visit; (2) Outcome #2 whether a 
patient received a non-prescription drug during the visit; and (3) Outcome #3 whether a 
patient was given an IV during the visit. For each outcome, I address the following 
questions. 
1. Is there an association between patient wait time and probability of 
receiving medication? 
2. What are the other determinants of the medication outcomes? 
3. What are the macro-trends over the five years of data of the medication 
outcomes? 
I use logistic regressions to estimate the relationships between the three medication 
outcomes and my key independent variable of wait time. My control variables include 
demographic information, payment method, clinical characteristics, and year indicators.  
E. DATA USED 
My data comes from the National Center for Health Statistics (NCHS), an 
organization that falls within the Center for Disease Control (CDC). NCHS sends each 
respective state in the U.S. a survey, who in turn sends these surveys to hospitals with an 
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ED in order to solicit responses. I use data for years 2012 to 2016 in my analysis. The 
survey is called the National Hospital Ambulatory Medical Care Survey (NHAMCS). The 
data in these surveys is reported at the individual/patient level for my 98,451 total 
observations, but there are no unique identifiers to track individual patients from one year 
to the next.  
F. SCOPE AND METHODOLOGY   
To analyze the NHAMCS data I run multivariate logit models focusing on relevant 
variables identified based on my literature review and my key explanatory variable of wait 
time. In my first outcome variable (Outcome #1) I test the hypothesis that patients who 
wait longer are more likely to receive a medication. My data does not give me specific 
information on number of work hours worked by providers so I proxy longer wait times by 
splitting them into quartiles. The quartiles of time allow me to capture potential nonlinear 
relationship between wait time and the likelihood of a patient being prescribed any 
medication.  
My Outcome #2 is the probability of a patient receiving a non-prescription drug 
and Outcome #3 is the probability of an IV being given to a patient. I include these two 
latter outcome variables in my research to get additional insights on whether the association 
between wait time and medication outcomes might differ depending on different aspects 
of medication as I compare the results of each respective outcome.  
G. FINDINGS 
My findings show that patients in the 4th quartile of wait time have lower odds of 
receiving a medication, patients in the 3rd quartile have lower odds of receiving a non-
prescription drug, and patients in the 2nd, 3rd, and 4th quartile have lower odds of being 
given an IV. In all three outcome variables there is a decreased likelihood for a patient to 
receive a medication, receive a non-prescription drug, and be given an IV due to wait times 
longer than 8 minutes.  
I also find many control variables that are correlated with all three outcomes such 
as age, sex, race, ethnicity, payment method, pain scale, and symptoms. For example, in 
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Outcome #1 patients experiencing severe pain and patients with pain and fever symptoms 
are 2.168 and 1.776 times more likely to receive a medication, respectively. In Outcome 
#2 these two variables are still good indicators of increasing the likelihood of receiving a 
non-prescription drug, but so is heart and chest pain (not heartburn) who are 1.686 times 
more likely. These findings and more are discussed in further detail in Chapter IV.  
This thesis includes the following chapters organized as follows: Chapter II is my 
literature review focusing on the following areas: (1) previous research on NHAMCS and 
NAMCS data and their findings; (2) prior research on the effectiveness of prescribing 
policy programs and their findings. Chapter III covers in detail the data and method used 
to run my analysis. Chapter IV has my descriptive summary statistics table as well as the 
results of my logistic regressions for my three outcome variables. This chapter also 
discusses the key findings from my quantitative analysis. Lastly, Chapter V covers my 
conclusion from my analysis and recommendations to include my thoughts on what further 
research should be done in the future. 
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II. LITERATURE REVIEW 
A. OVERVIEW 
Over the last few decades much research and focus has been placed on the opioid 
epidemic happening in the United States. Due to this epidemic, much research exists 
surrounding opioid-specific drugs and the prescribing patterns associated with them, but I 
do not find any prior research specific to my primary outcome (determinants of any drug 
prescribed). I find this research on opioid drugs helpful because I am able to see and 
compare results of their determinants and mine using similar variables. Additionally, my 
literature review includes helpful research that uses the same survey dataset 
(NHAMCS/NAMCS). One of the main recommendations from opioid related research is 
a recommendation for hospitals to use a medication prescribing policy program. These 
policies are aimed at raising awareness and curbing the opioid epidemic. I dive into 
conflicting results of these programs to better understand if they influence the likelihood 
of any drug being prescribed. I conclude with a summary of the main takeaways from my 
literature review.  
B. PREVIOUS RESEARCH ON NHAMCS AND NAMCS SURVEY DATA  
1. Findings on Pain, Symptoms, Sex, Race, and Ethnicity 
The initial focus of my literature review is prior research conducted on survey data 
from NHAMCS and NAMCS database, the same (or comparable) data I use in my study. 
The following articles look at a patient’s primary complaint (i.e., pain scale and symptoms) 
as well as demographic characteristics such as age, sex, race, and ethnicity. I believe pain 
and symptom characteristics make up the bulk of interest in determinants of doctors 
prescribing a drug since they are primarily made up of traits patients have as they enter the 
ED. These traits provide useful and meaningful insight into aggregate trends in the U.S. 
healthcare system. For example, if patients (over time) show an increased likelihood of 
claiming higher pain levels, or specific symptoms show up in higher frequency, this type 
of information is helpful to know if they influence type of treatments received during an 
ED visit. 
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Lin et al. (2019) identify variables that increased the likelihood of an opioid being 
prescribed. They find that opioid medications are more likely to be prescribed when a 
patient noted both pain and depression as a symptom. The main takeaway from this 
research is that the pain and depression symptoms appear to increase the likelihood that an 
opioid was prescribed during a visit (Lin et al., 2019). Depression is of primary interest for 
providers of opioid drugs due to suicide related incidences, but it is not a characteristic 
used in my research. Instead, I focus on the patients reported pain levels and symptoms in 
my research to see if these initial patient reporting characteristics could be signals or 
determinants of a prescription or non-prescription drug being prescribed, and/or whether 
any of them have a relationship with an IV being given.  
Another finding in the Lin et al. (2019) study is that white males between the age 
of 46–64 are more likely to be prescribed a narcotic analgesic. This type of finding suggests 
to ED’s that patients falling into this category (white male, aged 46–64) may have unique 
underlying symptoms or conditions that increase their likelihood of being prescribed a 
narcotic. A separate study by Qureshi (2017) finds no relationship between race (White, 
Black, or Other). But, Qureshi does find that that when looking at the gross total amount 
of opioids prescribed, White males aged 50–64 do receive the most opioid prescriptions. 
Based on Lin et al. and Qureshi’s research, there appears to be indications that White males 
in the age range of 50s to 60s receive a larger portion of opioid prescriptions but that does 
not translate into higher prescribing rates. Lin et al.’s and Qureshi’s findings do conflict 
with one another. Lin et al. finds that race (being White) increases the likelihood of being 
prescribed a medication but Qureshi’s findings state there is no relationship between this 
outcome and race.  
Again, the focus of these studies are opioid-specific, but in my analysis I look at 
gender and race to see if there are any significant differences between the groups over the 
five years of data. I do not expect to find exactly similar results because my research is not 
opioid-focused. My research analyzes the effects demographics (sex, race, and ethnicity) 
have as a determinant of any drug or non-prescription drug being prescribed, or an IV being 
given. Additionally, I include payment type (i.e., private insurance, self-pay, Medicare, 
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Medicaid, and other-pay) as a trait that each patient would have to see if any have a 
significant relationship with my outcome variables. 
The next finding comes from Ashman et al. (2019) who finds that females have a 
higher visit rate to physicians than males, as well as infants and the elderly. To define the 
infant and elderly population this study excludes those aged 1–64. This is interesting 
because previous articles mention older White males as receiving the most opioid drug 
prescriptions, but this article suggests females have higher visit rates. While this study does 
not analyze the likelihood of a female being prescribed a medication based on higher visit 
rates, it does explain why they make up a higher percentage of visits in my analysis. The 
question remains, since females have a higher visit rate, does that make them more likely 
to receive a medication, receive a non-prescription drug, or be given an IV? 
Additionally, Ashman et al. (2019) find that chronic conditions (e.g., cancer, kidney 
disease, diabetes) make up the majority of visits to the physician, for a total of 37% of all 
visits. Ashman et al. find that these types of conditions are higher for adults than children, 
which is expected since many chronic conditions appear in older patients. This finding on 
chronic conditions driving higher physician visits might also indicate that these same 
patients are more likely to need a prescription or non-prescription drug. The last finding 
from this study is that children’s visits usually stem from new problems or some kind of 
preventative care whereas adults are usually visiting physicians for pre- or post-surgery 
care needs (2019). Based on Ashman et al.’s article, I believe the best method for analyzing 
determinants for my three outcome variables is to focus on pain scales and symptoms. I do 
not analyze specific pre- or post-surgery conditions of patients in my analysis.   
Rasu & Knell (2018) also looked into factors that increase the likelihood of an 
opioid being prescribed and find that as a patient’s age increased, opioid use also increased. 
This study is similar to the Lin et al. study, but varies slightly in age ranges. In the Rasu 
study they find opioid use increased for those aged 35–49 and are more than 1.37 times 
more likely to be prescribed an opioid when compared to the reference group aged 18–34. 
They also find that this likelihood decreases after the age of 65, where it becomes 0.61 
times less likely than the reference group (2018). In my thesis I analyze any relationship 
age has with our three outcome variables to see if aging affects the probabilities. Rasu & 
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Knell also find a higher opioid prescribing rate for patients reporting symptoms of general 
chronic pain, specific to the southern region of the U.S. The reporting symptom is of 
interest in my research as I look at the main reported symptoms that may increase or 
decrease the likelihood of a drug being prescribed.  
Lastly, the Rasu & Knell study finds that patients of Hispanic ethnicity and those 
who used private insurance are less likely to receive a prescription for an opioid drug 
(2018). This is a unique finding to the Rasu & Knell study, and it is something I evaluate 
further in my analysis as I include Hispanic and payment type in my research. Rasu & 
Knell’s findings seem to suggest that patients that claim Hispanic are less likely to be 
prescribed an opioid. My analysis looks at three separate outcome variables in an attempt 
to see if there is in fact any type of relationship between a patient being Hispanic to be 
compared against the Rasu & Knell findings. I also dive further into payment type to see if 
there are any trends or relationships between various sources of payment (private 
insurance, self-pay, Medicare, Medicaid, and other-pay).  
The results of the previous authors and research are evaluated against my findings, 
but I do not expect the exact same results since my study is not opioid-specific. However, 
there may be similar findings worth noting such as race, ethnicity, payment method, or 
patients reported symptoms, all of which are evaluated in my analysis.  
2. Findings on Patient Wait Time / Length of Visit 
Qureshi (2017) finds that patients who have a longer wait time, or length of stay, 
are more likely to be prescribed an opioid drug. Qureshi analyzes total time patients spend 
with a physician and finds that a patient with a length of visit over 30 minutes is more 
likely to be prescribed an opioid. I believe this finding is interesting and it is useful to use 
as a comparison to the findings in my research.  
While these times are somewhat different (wait time versus length of visit) it may 
indicate that certain patients are willing to wait longer or stay with a provider longer in 
order to get a prescription need met.  I make this comment because Qureshi’s study also 
indicates that the overall average time a patient spends during their visit is 11–20 minutes 
(2017). Again, I believe this finding suggests that patients who are seeking an opioid or 
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any drug related need, may be willing to wait longer than average since Qureshi also finds 
that those with visit lengths over 30 minutes are more likely to be prescribed an opioid. 
This is of keen interest to my analysis as it points to the fact that wait times can in fact have 
an impact on whether a patient received a medication.  
C. EFFECTIVENESS OF PRESCRIBING POLICY PROGRAMS 
1. Findings Suggest Minimal (if any) Effectiveness from Programs 
An additional theme I find in my literature review involves the effectiveness of 
prescribing policies within the healthcare system. Menchine et al. (2017) conduct analysis 
on such policy programs in their critique of a previous study completed by Barnett et al. 
(2017). Menchine et al. suggests Barnet et al. incorrectly interpreted their key findings, 
which suggests that emergency physicians are key drivers of the opioid epidemic (Barnett 
et al. 2016). The main takeaway from the Barnett et al. study is that physicians over-
prescribe opioid drugs (more likely to prescribe, meaning a higher prescribing pattern 
would be evident) whereas Menchine et al.’s team does not agree with these findings. 
In Menchine et al.’s study, they state that Barnett et al.’s team incorrectly concluded 
that clinical providers prescribe too many opioids, because their analysis is biased. 
Menchine et al. goes on to say that Barnett et al.’s study may have lacked clear detail on 
the factors that truly impact higher prescribing rates of opioid drugs to patients. According 
to Menchine et al. (2017), emergency room visits only account for 5% of all opioids 
prescribed. Additionally, he states that “together these data suggest that interventions in 
the emergency department to reduce prescribing have a low potential to reduce long-term 
opioid use” (Menchine et al., 2017, p. 1895). This study finds that the variance between 
provider types (i.e., low-versus-high intensity prescribers of opioids) only varies by 0.35%. 
This is a very small and almost negligible variance between the two provider types 
analyzed by Menchine et al. 
The “interventions” are of primary interest to me as I am looking at factors that 
increase or decrease the likelihood of a patient receiving a medication. I can infer from this 
study that these interventions had minimal effect on long-term opioid use.  This study also 
stresses the fact that opioid prescription reduction should not be focused solely on 
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emergency departments as they only make up a small portion of the prescriptions written. 
The bottom line is that clinicians appear to be prescribing medications consistently, with 
or without an intervention program to curtail opioid prescribing patterns. I carry this 
assumption in to my study as my data does not include prescribing policies as an option to 
analyze. 
2. Findings Suggest “Hope” for Programs (inconclusive)  
In contrast to Menchine et al. another article and analysis from Sowicz et al. finds 
the following: “variability in clinician, facility, and region-level prescribing patterns 
suggests that interventions to curtail high prescribing of opioids can be designed with the 
hope of affecting change on one or more levels” (Sowicz et al., 2018, p. 1832). This 
research appears to indicate that if a hospital uses a prescribing policy, it can in fact affect 
prescribing patterns of providers. This is interesting because of its contrary findings to that 
of Menchine et al.’s study. 
The results from Sowicz et al. show that varying types of clinical providers may in 
fact have behaviorally different probabilities in prescribing medications if they are trained 
via some kind of prescribing policy. What I have already seen in prior research is that 
clinician type (physician versus non-physician) is irrelevant to prescribing patterns (i.e., no 
effect on the likelihood of a drug being prescribed). The research of Sowicz et al. (2018) 
suggests the “hope” that interventions like a prescribing policy could have an effect on 
prescribing patterns of clinical providers, which I interpret as inconclusive. The fact that 
Sowicz et al. use the word hope in their findings suggest that the possibility exists that 
prescribing policies could have a positive influence on curbing over-prescribing drugs 
(such as opioids). I take this finding as merely a possibility, not overwhelming evidence 
that programs such as these impact prescribing behaviors.  
3. Findings Suggest Program Decreases Opioid Prescriptions 
The third article under this prescribing policy program section is written by Chacko 
et al. (2017) and once again contradicts Menchine et al.’s findings and supports Sowicz et 
al. Chacko et al. finds that these types of programs have a clear effect on decreasing the 
overall prescription rates of opioid drugs. Chacko et al. goes on to acknowledge that 
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success of such programs would help to curb the epidemic facing the United States, but 
this assumes prescribing policy programs are effective in changing clinical providers 
prescribing behaviors. Again, the results of this study are opioid-specific, so I take these 
results into consideration as a possible intervention method that might positively or 
negatively influence prescribing behaviors. 
Given the results of this study, factors such as comparing EDs with and without this 
type of policy should be considered in future studies that choose to expand on the results 
seen in my research. This would require a control and treatment group—comparing EDs 
with and without some kind of prescribing policy—to then compare the prescribing rates 
of all clinical providers over time. Unfortunately, my dataset does not include any variable 
or method of tracking whether an ED had this type of program in place, so it not included 
in my models.  
D. SUMMARY 
The study conducted by Lin et al.’s team show indications that certain pain and 
symptom variables increase the likelihood of a drug (opioid) being prescribed. In my 
analysis I control for pain scale indicators as well as symptoms reported by patients to see 
if they affect my outcome variables. Additionally, multiple articles above find differential 
results based on age, sex, and race. For example, Qureshi (2017) did not find any 
correlation between race (White, Black, or Other) and a drug being prescribed, but did find 
that males aged 50–64 are prescribed the most opioid drugs. Also, women have higher visit 
rates to a physician than men (Ashman et al. 2019) but it is unclear if that corresponds with 
higher likelihoods of a drug being prescribed, so these traits are included and compared to 
in my analysis. With respect to the results of infants and elderly visit rates exceeding those 
between ages 1 and 64, my analysis evaluates any relationship between age and my three 
outcomes.  
When I review literature on prescription policy related programs I find mixed 
results and conclusions. Based on these findings, I loosely interpret this data as indicating 
that additional prescription prescribing oversight programs have minimal impact on the 
likelihood of a patient being prescribed a medication. These findings are interesting for my 
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analysis, but I assume this type of intervention has minimal to zero effect on prescribing 
patterns of providers. I believe omitting this type of observation does not bias my results, 
but I recommend future researchers include this type of observation in future studies to 
further assess whether it could impact prescribing patterns. I do acknowledge the 
possibility that such programs may have or may not have been in place at the respective 
EDs in my dataset, but it is not possible to identify since the surveys I analyze do not 
include such observations. 
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III. DATA AND METHODOLOGY 
This chapter describes the data I use in my analysis, to include the three outcome 
variables, key independent variables, and various control variables to predict each 
outcome.  
A. DESCRIPTION OF DATA AND SAMPLE POPULATION 
The data set that I analyze is from the National Center for Health Statistics (NCHS), 
which operates within the Center for Disease Control (CDC). In 2002 NCHS started a 
nationwide survey called the National Hospital Ambulatory Medical Care Survey 
(NHAMCS). This survey is sent to each respective state who are responsible for soliciting 
inputs form its hospitals within their state. The surveys are collected at the state level, the 
sent to the CDC/NCHS. Each observation represents a unique ED visits. It is possible that 
the same patient made multiple visits to the ED, in which case the patient would appear 
multiple times in the data. Data received by NCHS goes through multiple consistency and 
quality control checks with coding error rates ranging between 0.1 and 1.5% when sampled 
(NHAMCS, 2016). For my thesis research I combine and analyze calendar years 2012–
2016 which includes 98,451 total observations across five years.  
The surveys are sent to about 450 hospitals each year, of which approximately 250 
random hospitals submit responses, and these are recorded in micro-data files available 
from the NCHS website. Due to privacy and confidentiality concerns, this dataset does not 
include unique identifiers for patients or hospitals since it is a public use dataset. Meaning, 
there is no way to observe a single unique identity (patient or hospital) over the five years 
of data. Each respective state collects the survey, then randomly assign a unique 3-digit 
number known as a code to each hospital so end-users of the data have no way of knowing 
which hospital it is analyzing. Therefore, it is impossible to analyze this publicly available 
data for specific geographic locations by zip code, nor is it possible to track any individual 
patient or hospital through the years.  
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B. KEY VARIABLES 
Based on the literature review and personal objectives of this thesis I have come up 
with the following outcome and independent variables to use in my analysis. In the 
following sections I briefly explain the three outcome variables: Outcome #1 (any 
medication), Outcome #2 (non-prescription drug), and Outcome #3 (IV). I also explain 
how I analyze the key independent variable, wait time, as measured with indicators for the 
quartiles of the wait time distribution. Following that I discuss the control variables that 
are broken up into five categories: demographic information, payment method, clinical 
characteristics, and year. Each respective outcome variable is analyzed in my regression 
models with the same key independent variable (wait time) and control variables 
(previously mentioned) to maintain uniformity and easily compare results of each 
respective variable against various outcomes.  
1. Outcome Variables 
This research analyzed three different outcome variables described below. 
a. Outcome #1 - Medication (Probability of receiving a medication) 
Outcome #1 is a binary outcome that captures whether a patient received any 
medication (yes or no response on the survey) during his ED visit. In the survey if a patient 
received any medication it would be marked as “yes,” which has a value of 1 in the dataset. 
Alternatively, if the patient does not receive any medications during their visit to the ED it 
would be marked as “no,” which carried a value of 0 in the dataset. This outcome variable 
is binary, so a patient either received a medication or did not. I do not distinguish between 
drug class (prescription vs non-prescription) with this outcome variable. It includes any 
type of medication given. I have inserted Table 1 as a reference point so readers can easily 




Table 1. Outcome #1 Medication, Dependent Variable Summary 
Dependent Variable Variable Definition 
Medication = 1 if patient received a medication during ED visit or 
discharge; otherwise = 0 
Variable Observations Mean Std. Dev. Min Max 




No (=0) 18,041 18.32 
Yes (=1) 80,451 81.68 
Total 98,451 100.00 
 
As seen in Table 1 the majority of patients were prescribed a medication (81.68% 
of the sample size population). Outcome #1 is not focused on differentiating between types 
of drug class, instead the purpose is to look at all drug types. 
b. Outcome #2 - Non-Prescription Drugs (Probability of receiving a non-
prescription drug) 
Outcome #2 is also a binary outcome that captures whether a patient received any 
drug labeled as non-prescription during their ED visit. In the survey dataset up to 30 
different types of medication are tracked and coded in the dataset. If a patient is given any 
non-prescription drug it is labeled as “non-prescription” or “prescriptions and non-
prescription.”  Meaning, a patient that received any non-prescription drug may have also 
received a prescription drug.  
I generate a new variable to capture these observations in order to analyze the 
probability of any non-prescription drug being prescribed. I have inserted Table 2 as a 
reference point so readers can easily refer back to the definition and summary statistics for 




Table 2. Outcome #2 Non-prescription, Dependent Variable 
Summary 
Dependent Variable Variable Definition 
Non-Prescription = 1 if patient received a non-prescription drug during ED visit 
or at discharge; otherwise = 0 
Variable Observations Mean Std. Dev. Min Max 
Non-
Prescription 
98,451 .533 .499 0 1 
Was a Non-Prescription 
Drug Received 
Frequency Percent 
No (=0) 45,941 46.66 
Yes (=1) 52,510 53.34 
Total 98,451 100.00 
 
As seen in Table 2 a little more than half of all patients receive a non-prescription 
drug (53.33% of the sample population). Contrary to Outcome #1, Outcome #2 focuses on 
the likelihood of a patient receiving a non-prescription drug during their visit to the ED vs 
receiving any medication. 
c. Outcome #3 - IV Fluids (Probability of an IV being given to a patient) 
Outcome #3 is a binary outcome that captures whether a patient received any IV 
(yes or no response on the survey) during their ED visit. In the survey if a patient received 
an IV it would be marked as “yes,” which carries a value of 1 in the dataset. Alternatively, 
if the patient does not receive an IV during their visit to the ED it would be marked as “no,” 
which carries a value of 0 in the dataset. I have inserted Table 3 as a reference point so 






Table 3. Outcome #3 IV Fluids, Dependent Variable Summary 
Dependent Variable Variable Definition 
IV Fluids = 1 if IV was given during ED visit; otherwise = 0 
Variable Observations Mean Std. Dev. Min Max 
IV Fluids 98,451 .264 .441 0 1 
Was a Non-Prescription 
Drug Prescribed 
Frequency Percent 
No (=0) 72,419 73.56 
Yes (=1) 26,032 26.44 
Total 98,451 100.00 
 
As seen in Table 3, 26.4% of patients are given an IV during their visit. This is a 
much smaller percentage of patients when compared to Outcome #1 and #2, but a patient 
given an IV is also a much different intervention than receiving a type of medication.  
2. Independent Variable 
The key independent variable I use in this study is the patient’s wait time. Patients 
wait time is recorded in minutes in the survey data. As stated in Chapter I, the primary 
purpose of this analysis is to understand whether overworked providers are more or less 
likely to prescribe medication to a patient. In order to get a better understanding of wait 
time and whether it has any relationship to various outcomes in care, I include it as the key 
independent variable for all three outcomes previously discussed.  
I use the wait time recorded in the surveys as a proxy for whether the emergency 
department is under high patient demand (overworked) or not. Patients who had to wait 
longer than the average are considered to be seen by overworked EDs, whereas patients 
seen earlier than the average wait time are not. The method I choose to break up and analyze 
wait time is in quartiles, therefore each respective category of wait time has an equal share 
of 25% of the total observations. This allows me to analyze differences in various wait 
times, as well as easily address my original goal to understand if longer than average wait 
times have a significant relationship to any of my outcomes. I proxy longer wait times by 
looking at patients seen in the 3rd and 4th quartiles of wait time as seen in Table 4.  
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Table 4. Key Independent Variable, Wait Time Summary 
Wait Time Category Waiting time to see a provider (MD/DO/PA/NP) in 
minutes. Median (Interquartile Range) 
1st Quartile 3 (5) minutes 
2nd Quartile 14 (6) minutes 
3rd Quartile 30 (13) minutes 
4th Quartile 84 (68) minutes 
Overall 20 (39) minutes 
Variable Observations Mean Std. Dev. Min Max 
Wait Time 98,451 41.733 71.975 0 1,440 
 
My intent with wait time is to analyze the entire dataset of observations (98,451 
total observations) in a categorized wait time methodology. This method allows me to 
categorize wait times in the primary quartiles in which they fall (1st Quartile 0–25%, 2nd 
Quartile 25–50%, 3rd Quartile 50–75%, and 4th Quartile 75–100% of observations). I 
believe this method is necessary in order to capture the true effect (if any) that various wait 
times have on patients for each respective outcome variable. As seen in the summary 
statistics, wait times are very skewed to the right with some patients waiting for a very long 
time before seeing a provider. The categorical variable has two advantages over the 
continuous variable: (1) it can capture potential nonlinear relationship between wait time 
and the outcomes; (2) it minimizes potential estimation problems due to outlier.  
3. Control Variables 
The wide range of control variables used in this study help me identify potential 
determinants of doctors prescribing a drug, outside of my key independent variable wait 
time. The following paragraphs cover main categories I use in my research: demographic 
information, payment method, clinical characteristics, and years. The summary statistics 
for all of these control variables are in Table 5. 
a. Demographic Information 
The tables in Chapter IV reflect the four types of models run for each respective 
outcome variable, with demographic information being added in Models 2, 3, and 4. The 
category of demographic information includes the following: age, age-squared, female, 
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White (reference group), Black, Asian, Race-Other, and Hispanic. I consider these 
variables to be very helpful due to the fact that most of the studies I reviewed in my 
literature review also include them.  
Age and age-squared are helpful in my analysis for all three outcomes because it 
gives me insight into how significant age affects each outcome. For example, does aging 
greatly increase the likelihood a patient will receive a medication or be given an IV?  
Additionally, including patient’s sex is standard practice for studies similar to mine, and is 
helpful for comparison purposes. Recalling an earlier question I posed in the literature 
review, if females are more likely to visit physicians are they also more likely to receive a 
medication, receive a non-prescription drug, and/or be given an IV when compared to 
males?  I answer this question based on my results in Chapter IV. 
I also include race and ethnicity since it appears to be a standard practice based on 
the results of my literature review. My race variables include: White, Black, Asian, and 
Race-Other. The first three are self-explanatory, if the patient answered yes to any of the 
three questions (White, Black, or Asian) then the observation would record one single race. 
If the patient responded with any of the following they are put into the Race-Other variable: 
American Indian/Alaska Native (AIAN), Native Hawaiian/Other Pacific Islander 
(NHOPI), more than one race reported, or if the patient left it blank. 
b. Payment Method 
As seen in Chapter IV, I add payment method to Models 3 and 4. I include payment 
method to analyze whether any relationship exists between patients’ payment method and 
my outcome variables. I create indicator variables for the different types of payment 
methods used. The reference group for this variable is any patient who used private 
insurance. The remaining payment method for a patient are as follows: self-pay (patient 
paid out of pocket), Medicare, Medicaid or CHIP, or other payment method. The last 
category of others includes the following: worker’s compensation insurance, no charge to 
the patient, charity, or unknown.  
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c. Clinical Characteristics 
I add clinical characteristics in Model 4 for each respective outcome. Clinical 
characteristics include indicators for the following: if the patient was seen in the last 72 
hours, patient arrived by ambulance (a rough proxy for severity of illness), patient reports 
an experience of severe pain (pain scale > 5 on a scale 1–10), a binary indicator capturing 
unknown or missing pain scale (since over 1/3 of patients have missing information on 
pain scale), patient reporting heart or chest pain (not heartburn), and patients reporting pain 
and fever. The primary goal of these characteristic is to help understand any relationship 
of a pain or symptom that patients arrive to the ED with, and how they affect the outcomes 
in my models.  
All of the variables in this section are captured in a binary fashion for regression 
analysis. For example, if the patient was seen in the ED within the last 72 hours, arrived 
by an ambulance, and reports a pain scale greater than 5 on a 10-point scale, the value in 
the dataset would be =1. Additionally, with respect to how patients filled out their pain 
scale when they arrived at the ED, any patient that left it blank or had an unknown response 
are put into a separate variable for my analysis (pain scale unknown / left blank). 
There are a number of ways to capture various types of symptoms in this dataset, 
but I choose to create two new variables to analyze specific traits. These included the 
following two variables: 1) heart or chest pain (not heartburn); and 2) symptoms of pain 
and fever. My intent is to understand whether these types of specific ailments, present at 
patients’ arrival to the ED, could potentially have a relationship to being receiving a 
medication, receiving a non-prescription drug, and/or being given an IV. I believe these 
types of symptoms are relatively common and my data had sufficient observations of these 
traits so they are worth analyzing with my three outcome variables. 
d. Year 
I have included dummy variables for years in all four models (Model 1, 2, 3, and 
4). The reference group is year 2012, so each respective following year is compared to 
2012. The purpose of including these variables is to capture macro-trends that may be 
present over time. For example, are ED’s more or less likely to prescribe a medication, or 
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a non-prescription drug, or give a patient an IV in 2016 vs 2012?  This information should 
be useful in understanding the macro-trends that are present in the U.S. healthcare system. 
If prescribing rates are increasing over time it could lead to future research into potential 
unknown drivers of this increase over time. 
C. METHODS 
1. Logistic Regression Model 
I use a quantitative approach to analyze my data, through logistic regression 
analysis (LOGIT) with odds ratio (OR) to represent the effects of my key indicator and 
control variables on my three outcome variables. The primary purpose of using this type 
of model is to evaluate variables that increase or decrease the likelihood of a patient 
receiving a medication for Outcome #1. I also study two other outcomes, namely Outcome 
#2 indicator for a non-prescription drug being received and #3 indicator for whether an IV 
was given, both of which use the same LOGIT OR regression for analysis. 
I apply the same process and methodology for all three outcomes, as I analyze them 
using the same four models (Model 1, 2, 3, and 4). As seen in the outcome tables in Chapter 
IV, Model 1 only includes my key independent variable of wait time, which is in quartile 
categories and year indicators to capture macro-trend. This is the basic analysis to see the 
overall (net) relationship between wait time and my three outcome variables.  
The next step for Model 2 is to add in the demographic information: age, age-
squared, female, White, Black, Asian, Race-Other, and Hispanic. The intent here is to 
review basic demographic information to see if any of them have a significant relationship 
to my outcomes variables. It also allows a comparison to Model 1 to see if the relationship 
between wait time and medication outcomes changed significantly when taking into 
account patient demographics. This model helps to establish any baseline significance of 
various demographic traits which I can then compare to as I add in additional variables in 
Models 3 and 4. 
My next step for Model 3 includes variables from the previous two models, but it 
also adds in payment methods. The patient’s payment method is an interesting variable to 
observe between all three outcomes as it paints a picture of the type of patient seeking 
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various types of care. For example, do Medicare patients have a statistically significant 
relationship indicating they are more likely to receive an IV, but not a medication or a non-
prescription drug?  The results of Model 3 should be of keen interest to the U.S. government 
as the primary financial burden falls upon the government to fund Medicare and Medicaid 
programs. Understanding trends within the ED and its respective patients could lead to 
future cost-saving initiatives. 
The fourth and final model for all three outcomes is Model 4, and it builds on the 
prior models by adding in clinical characteristics, to see their effects on my outcome 
variables. Once again, finding trends between the various outcomes could help ED staff 
better understand their patients. For example, if a patient arrives by ambulance are they 
more likely to receive an IV, but less likely to be prescribed any drug/medication?  If so, 
why is that the case?  This final model does help me to understand how certain 
characteristics, usually present as the patient is admitted to the ED, could lead to higher or 
lower likelihoods of a patient receiving a medication, receiving a non-prescription drug, or 
given an IV. 
D. SUMMARY 
The primary focus of my research is to analyze any determinant that can increase 
or decrease the probability of a patient receiving a medication, receiving a non-prescription 
drug, and/or being given an IV.  Due to this focus I believe logistic regressions in odds 
ratio (LOGIT OR) is the appropriate model in this context. Data used from NHAMCS 
come as individual years but I want to analyze potential determinants based on a longer 
time horizon, hence the 5 years of combined data. It is possible to analyze individual years 
for outcomes, but I believe I have captured macro-trends over time by including dummy 
variables for year, omitting 2012, and focusing on whether 2013, 2014, 2015, and 2016 
had a higher or lower probability of prescribing over 2012. The results are discussed in 





This chapter discusses the results from the four models for each respective outcome 
described in Chapter III. The results for these logit regressions are presented in table format 
for each respective outcome, starting with medications, then non-prescriptions, then IV 
fluids. I conclude this chapter with a summary of key takeaways. 
A. DESCRIPTIVE STATISTICS 
The summary table of descriptive statistics can be seen in Table 5 starting with the 
first column that summarizes the entire sample size of 98,541 observations. Going from 
left to right, I have included 3 categories of summary statistics: Whole Sample, Patient 
Without a Medication, and Patient with a Prescription. There are a total of 18,041 
observations in the patient without a prescription column.  Consequently, there are a total 
of 80,410 observations in the patient with a prescription column. Meaning, patients that 
received any type of medication make up 81.7% of the whole sample, whereas patients that 
do not receive any medication make up the remaining 18.3% of the whole sample. This 
indicates that a high majority of patients receive a medication during their visit to the ED. 
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Table 5. Descriptive Statistics (Summary Table) 
 Whole Sample Patient does not 
receive a Medication 
(“No” response) 
Patient does receive a 
Medication  
(“Yes” response) 
Variable Description Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. 
Outcome       
Patient Received a 
Medication? 
.817 .387 N/A N/A N/A N/A 
Patient Received a 
Non-Prescription 
Drug? 
.533 .498 N/A N/A .653 .476 
Patient Given an 
IV? 
.264 .441 .091 .288 .303 .459 
Demographic Info       
Age 37.970 24.11 36.406 26.061 38.321 23.636 
Female .550 .498 .529 .499 .554 .497 
White .602 .490 .605 .489 .601 .490 
Black .198 .399 .190 .392 .200 .400 
Asian .017 .131 .020 .14 .017 .128 
Race - Other .183 .387 .185 .388 .182 .386 
Hispanic  .162 .368 .169 .375 .160 .367 
Payment Method       
Private Insurance .352 .478 .347 .476 .353 .478 
Self-Pay .135 .342 .116 .321 .140 .347 
Medicare .187 .390 .197 .398 .185 .388 
Medicaid or CHIP .350 .477 .358 .479 .348 .476 
Pay - Other: 
Workers Comp, No 
Charge, Charity, 
Unknown 
.115 .320 .121 .326 .114 .318 
Clinical Characteristics       
Seen in Last 72 
Hours 
.039 .194 .047 .211 .037 .189 
Patient Arrived by 
Ambulance 
.157 .364 .172 .377 .154 .361 
Experience Severe 
Pain (pain scale >5) 
.357 .479 .206 .404 .391 .488 
Pain Scale 
Unknown / Left 
Blank 
.267 .442 .326 .469 .253 .435 
Heart/Chest Pain 
(not heartburn) 
.052 .223 .045 .208 .054 .226 
Pain and Fever .187 .390 .116 .320 .202 .402 
Total Observations 98,451 18,041 80,410 
Note:  Omitted reference groups include male, White, private insurance, and year 2012 for their 
respective categories. 
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1. Whole Sample Descriptive Statistics 
One of my main takeaways from the whole sample column is that 81.7% of the 
patients in my sample population received a medication. If you look at the column which 
includes all patients that received a medication, 65.3% of them received a non-prescription 
drug. Lastly, 30.3% of these patients received an IV.  
The next interesting statistic that stands out is the mean percentage of patients who 
received an IV. As seen in Table 5, for patients that do not receive a medication, only 9.1% 
receive an IV vs 30.3% for those patients that received a medication. This is a large 
variance, but it is not too alarming since patients that get an IV put in during an ED visit 
are more likely to receive some kind of medication with it. I would assume that the smaller 
9.1% population that received an IV, as shown in the middle column, may have been in the 
ED for symptoms such as dehydration, where the hydrating effect of an IV is sufficient for 
purposes of care for that visit. That is just an assumption, but it is worth exploring why 
those who do not receive a medication appear to be less likely to receive an IV based on 
my analysis of the descriptive statistics table. 
The next takeaway from this table is the age across the three categories. 
Specifically, when looking at the mean age for patients that do not receive a medication, 
their age is ~36. Conversely, patients that receive a medication have a mean age of ~38. 
While they are relatively close in age, the variance of 2 years is somewhat interesting as it 
could be associated with general changes all adults experience as they get older. Based on 
these summary statistics, it appears to indicate that generally younger patients may be less 
likely to receive a medication during their ED visit. 
When looking at the clinical characteristics in the descriptive statistics table there 
are two variables worth discussing. The first one is the pain scale variable for patients that 
report severe pain (>5). Patients who report this level of pain make up a larger portion 
among patients who receive a medication totaling 39.1% of this sample, versus 20.6% of 
the population from patients that do not receive a medication. This shows me that a larger 
portion of patients that receive a medication come in reporting higher levels of pain versus 
those patients that do not receive any medication. Looking at the next pain scale variable 
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are those patients that left it blank or pain scale is unknown. For patients that do not receive 
a medication, 32.6% of this sample left pain scale blank or checked unknown, whereas for 
patients that receive a medication, 25.3% of this sample left pain scale blank or checked 
unknown. This appears to indicate that patients that end up receiving a medication are more 
likely to report higher levels of pain. This appears to be true since 39.1% of patients who 
receive a medication also reported high levels of pain, versus 20.6% of the sample of 
patients who do not receive a medication. Additionally, it could indicate that patients that 
leave pain scale blank or unknown are not seeking medication during their ED visit.  
2. Macro-Trends in Wait time and Medication Received 
In this section I discuss macro-trends for the following: (1) wait time trend (2012-
2016); and (2) percentage of patients that receive a medication and the percentage of 
patients that receive a non-prescription drug. Figure 1 represents the wait time trend over 
the five years of data. The main takeaway for this macro-trend is that wait time does appear 
to be decreasing over time, a good indication that EDs are already finding ways to become 
more efficient in decreasing the mean and median wait time a patient has prior to being 
seen. There is a slight uptick in wait time from 2012 to 2013, but it decreases in the 
following years. 




Figure 2 has two lines reflecting the macro-trends over the years 2012–2016 with 
respect to the percentage of patients that receive: (1) any medication; (2) a non-prescription 
drug; and (3) an IV. The trend for Outcome #1 and #2 increases, meaning a higher 
percentage of patients receive a medication and a non-prescription drug, respectively. 
Conversely, when looking at Outcome #3 there is a slight decrease in the percentage of 
patients that receive an IV, most noticeably in years 2012 and 2015 when ~25% of patients 
received an IV vs 28% in 2012. In my multivariate results section, I discuss the macro-
trends of all three outcome variables in greater detail within the four models. Figure 2 is a 
snapshot of the summary statistics results for Outcome #1, Outcome #2, and Outcome #3. 




B. MULTIVARIATE RESULTS 
The three outcomes described in my research are analyzed and presented separately 
in the following sections. All three outcome variables include the same four models 
discussed in Chapter III. Model 1 includes the quartile categories for wait time, Model 2 
adds demographic information, Model 3 adds in payment method, and Model 4 adds in 
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clinical characteristics. All four models include my key independent variable for wait time 
(in quartiles) as well as the year variables to compare macro-trends in the three outcomes.  
1. Outcome #1 – Probability of Receiving a Medication 
Table 6 presents the findings from the four models for Outcome #1 (medication) an 
indicator variable for any medication received by a patient. The key independent variable 
wait time, measured as a series of indicator variables for each quartile of the wait time 
distribution (1st, 2nd, 3rd, and 4th quartiles) is insignificant for Models 1, 2, and 3 but 
becomes statistically significant in Model 4. The 4th quartile of wait time in Model 4 shows 
patients who waited longer than 48 minutes have lower odds to receive a medication (by 
6%), after controlling for patient’s demographic, insurance, and clinical characteristics. 
Conversely, the remaining categories of wait time and remaining three models do not show 
any relationship between wait time and a patient receiving a medication during a visit to 
the ED. Below I discuss some of the other main takeaways from this regression as there 
are statistically significant variables that appear to have a relationship with Outcome #1 
(medication). 
Table 6. Outcome #1: Logistic Regression (Odds Ratio) Probability 
of Receiving a Medication  
Variable (Model 1) (Model 2) (Model 3) (Model 4) 
Wait Time (minutes)     
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Observations 98,451 98,451 98,451 98,451 
Note:  Omitted reference groups include male, White, private insurance, and year 2012 for their 
respective categories. 
Exponentiated coefficients; Standard errors in parentheses 
* p < 0.05, ** p < 0.01, *** p < 0.001 
 
a. Demographic Information Results for Outcome #1 (Medication) 
The demographic information variables are discussed in this section and the 
significant relationships these demographic variables have with Outcome #1 (medication), 
seen in Table 6.  There are mixed effects for Models 2, 3, and 4 for the following 
demographic information variables: age, female, Black, Asian, and Race-Other. The only 
variable in this outcome that shows no relationship to a patient receiving a medication is 
Hispanic. Additionally, age, Black, and Race-Other are the only variables that appear in 
Model 4. The variables that show significant relationships across multiple models are 
reviewed next. 
The age of a patient shows significance across Models 2, 3, and 4. The results 
indicate that older patients are more likely to receive medication but the rate of increase is 
not linear. The effect appears to be minimal, but this is expected based on similar findings 
in previous research discussed in the literature review section mentioning older individuals 
are more likely to be prescribed opioid drugs.  
An indicator for female patients also has mixed effects. For example, in Model 2 
and 3, we can see that female patients are 1.091 times more likely to receive a medication 
versus males. What is interesting is that there appears to be no significance in Model 4 for 
females when the clinical characteristics that captures experiences of pain are added into 
33 
the model. Still, this is an interesting finding as the literature review suggests females have 
higher visit rates, and the descriptive summary statistics (Table 5) also shows females 
receive more medications in the whole sample population. The regression suggests that the 
higher probability of female receiving medication in the literature is correlated with 
differences in pain experiences by gender. 
The next sub-category of variables I discuss are the race and ethnicity variables. I 
previously mentioned that Hispanic shows no significant relationship to medication, but 
there is a significant relationship for Black, Asian, and Race-Other. For patients that report 
being Black, all three models show they are 1.047-1.062 times more likely to receive a 
medication. Conversely, patients that report being Asian have lower odds to receive a 
medication (by 12.7-13%) in Models 2 and 3, with no significance in Model 4. The final 
variable in this section Race-Other shows a significant relationship in Model 4, reflecting 
these patients are 1.054 times more likely to receive a medication. 
b. Payment Method Results for Outcome #1 (Medication) 
The payment method variables are discussed next for Models 3 and 4 on Outcome 
#1.  The results from these Models show that patients that are self-pay, Medicare, and pay-
other have a statistically significant relationship with Outcome #1. The main takeaway is 
that Medicare is only significant in Model 3, showing lower odds to receive a medication 
(by 6.1%) compared to patients with private insurance, but is insignificant in Model 4. The 
remaining two significant variables (self-pay and pay-other) are discussed next. 
The interesting results for self-pay patients from Models 3 and 4 indicate these 
patients are 1.097-1.137 times more likely to receive a medication, when compared to 
patients with private insurance. This means that a patient that pays for their healthcare 
needs out of their own pocket are more likely to receive medication than a patient with 
private insurance. This could be due to the fact that these self-pay patients are more 
selective about when they go to the ED, so when they do they are seeking a medication to 
take care of their respective symptoms. This is just my hypothesis, but worth considering 
in future research. 
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The next category of pay is pay-other, which includes all observations of patients 
that use workers’ compensation insurance, no charge situations, charity, or unknown 
payment method. These patients, when compared to private insurance patients, have lower 
odds to receive a medication (by 9.2-9.4%) during their visit to the ED.  
c. Clinical Characteristics Results for Outcome # 1 (Medication) 
The clinical characteristics variables are discussed next for Model 4 on Outcome 
#1.  The results from this model are very interesting in my opinion because it shows the 
following variables to have a significant relationship to a medication being received by a 
patient:  seen in the last 72 hours, patient arrived by ambulance, experience severe pain 
(>5), heath/chest pain (not heartburn), and pain and fever symptoms. 
The first variable is whether a patient has been seen in that respective ED within 
the last 72 hours, and if the patient responded with yes they have lower odds to receiving 
a medication (by 24%). In addition to this variable if the patient arrived by ambulance, they 
also have lower odds to receive a medication (by 7.6%). Both of these findings are 
interesting but it is unclear to me why this would be the case. Normally, I would assume 
that a patient with repeat visits to the ED would be doing so due to ongoing issues that 
require some form of treatment, like a medication. Or, these repeat visits could be due to 
patients returning with similar symptoms and providers see an original prescription and 
instruct patients to continue with their original medication. Additionally, I think whenever 
a patient arrives by ambulance they too would be in higher need of a medication. But, the 
results of my analysis prove otherwise.  
This next variable is very interesting; it includes patients that reported experiencing 
severe levels of pain (>5 on a 10-point scale). A patient that marks a pain scale higher than 
5 is 2.17 times more likely to receive a medication. I think the obvious takeaway from this 
finding is that patients in severe levels of pain are most likely seeking care at the ED to 
alleviate the symptoms, and are legitimately in need of medication. It is interesting to see 
how these results compare to Outcome #2 where I analyze this same variable and its 
relationship to non-prescription drugs. Patients that left a blank or unknown response to 
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pain scale when they entered the ED do not appear to show any significant relationship 
with Outcome #1. 
The next two variables are symptomatic behaviors of patients: those reporting 
heart/chest pain (not heartburn) and separately those reporting pain and fever. Both 
variables indicate a higher likelihood of a patient receiving a medication. For those patients 
reporting heart/chest pain (not heartburn) they are 1.18 times more likely to receive a 
medication. For patients reporting pain and fever, they are 1.776 times more likely to 
receive a medication. I believe these results are similar to patients reporting severe levels 
of pain, where they are in some kind of imminent need of aid to alleviate their respective 
symptoms and seeking medications at the ED appears to be their solution. 
d. Macro-Trends in Years for Outcome #1 (Medication) 
The final observation I analyze in Table 6 are the results shown in the prescribing 
patterns from 2012 to 2016. In the table, 2012 is the omitted year group, so all subsequent 
years show an increased likelihood of a medication being received. This means that over 
time, EDs appear to be more likely to prescribe a medication when compared to previous 
years. But, it must be noted that the trend does not appear to consistently increase as 2014 
appears to be lower than 2013, and 2016 is lower in models 1, 2, and 3 when compared to 
2015. Figure 3 shows the trend for 2013–2016, when compared to the base year 2012. 
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Figure 3. Outcome #1 Probability of Receiving a Medication Macro-Trend 
2013–2016 (2012 is reference year) 
 
 
When comparing the latter two years (2015 and 2016) to the reference year 2012, 
a patient is 114.6-1.178 times more likely to receive a medication in the latter years. This 
is an interesting finding as it appears to suggest that over time, ED’s are more likely and 
patients are more likely to receive a medication, assuming they have comparable patient 
population (since Model 4 controls for underlying patient characteristics). This could be 
due to varying factors such as an aging population, affects from the Affordable Care Act 
(ACA), or defensive medicine by providers. These findings warrant additional research on 
prescribing rates over time to identify causes and solutions to slow the trend. 
2. Outcome #2 – Probability of Receiving a Non-prescription Drug 
Table 7 presents the findings from the four models for my second outcome variable 
an indicator variable for whether the patient received a non-prescription drug. The key 
independent variable wait time (broken into quartiles) is now statistically significant in the 
3rd quartile (21-47 minutes) in all four models. The results for the 3rd quartile of wait time 
shows that a patient waiting 21–47 minutes have lower odds to receiving a non-prescription 
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drug (by 3.8-4.2%) when compared to the reference category quartile 1 (patients who wait 
0–8 minutes). These findings suggest that as patients wait longer (when compared to the 
1st quartile of wait time), the likelihood of them receiving a non-prescription drug 
decreases, at least for the 3rd quartile of wait time.  
Table 7. Outcome #2: Logistic Regression (Odds Ratio) Probability 
of Receiving a Non-prescription Drug  
Variable (Model 1) (Model 2) (Model 3) (Model4) 
Wait Time (minutes)     
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Observations 98,451 98,451 98,451 98,451 
Note:  Omitted reference groups include male, White, private insurance, and year 2012 for their 
respective categories. 
Exponentiated coefficients; Standard errors in parentheses 
* p < 0.05, ** p < 0.01, *** p < 0.001 
 
39 
a. Demographic Information Results for Outcome #2 (Non-prescription) 
The demographic information variables are discussed next for all three models on 
Outcome #2.  Similar to Outcome #1, there are mixed results across Models 2, 3, and 4 for 
the following demographic variables: age, female, Asian, and Race-Other. Notably, the 
race variable Black is not statistically significant in any of the models for Outcome #2, 
whereas it is in Outcome #1. Also, previously Hispanic had no relationship to Outcome #1, 
but it appears highly significant in the models from Outcome #2. 
An indicator for female patients also has mixed effects in Outcome #2, similar to 
findings in Outcome #1. In Models 2,  3, and 4 the regression suggest a female patient has 
a higher probability of receiving a non-prescription drug. This shows that female patients 
are 1.028-1.085 times more likely to be prescribed a medication vs males, the same or 
similar results as Outcome #1. Model 4 is the only variance from Outcome #1 as it 
previously showed no relationship when controlling clinical characteristics, but it does 
show a relationship in Outcome #2. These results continue to indicate that females do have 
a slightly higher likelihood of receiving any medication and/or a non-prescription drug, 
compared to males. 
The next sub-category of variables includes race and ethnicity. In Outcome #1 a 
Hispanic patient does not show any significant relationship, but that is not true for the 
models in Outcome #2. In fact, a Hispanic patient is 1.096-1.113 times more likely to 
receive a non-prescription drug. These findings are interesting because it appears to 
indicate the possibility that Hispanic patients are more likely to be seen in the ED for a 
non-prescription drug need. 
In almost all models, an Asian patient is 1.15-1.189 times more likely to receive a 
non-prescription drug when compared to White patients. This is in direct contrast to 
Outcome #1 where they have lower odds to receive a medication. Similar to the Hispanic 
variable, this could indicate that more people of Asian race are likely to seek non-
prescription drug needs from the ED. Similar results are seen with patients of other races, 
who are 1.094-1.116 times more likely to receive a non-prescription drug when compared 
to White patients.  
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b. Payment Method Results for Outcome #2 (Non-prescription) 
The payment method variables are discussed next for Models 3 and 4 on Outcome 
#2.  The results from these models show that Medicare patients have lower odds to receive 
non-prescription drug compared to privately insured patients (by 4.9-5.8%). In the previous 
sections for Outcome #1 patients who use self-pay and pay-other show a significant 
relationship to receive any medication, but they have similar odds of receiving non-
prescription drugs as privately insured patients.  
c. Clinical Characteristics Results for Outcome #2 (Non-prescription) 
The clinical characteristics variables are discussed next for Model 4 on Outcome 
#2.  Similar to the results from Outcome #1, the results of the models run with Outcome 
#2 show the same variables have a significant relationship with receiving a non-
prescription drug: seen in the last 72 hours, patient arrived by ambulance, experience severe 
pain (>5), heath/chest pain (not heartburn), and pain and fever symptoms. 
The first variable is whether a patient has been seen in that respective ED within 
the last 72 hours, and in this outcome model these patients have lower odds to receive a 
non-prescription drug (by 18.1%). This is in comparison to the lower odds in Outcome #1 
(by 24%). If the patient arrived by ambulance, they are 1.17 times more likely to be receive 
a non-prescription drug. This is contrary to Outcome #1’s results indicating patients that 
arrive by ambulance have lower odds of receiving a medication (by 7.6%). These results 
are interesting because the likelihood of a patient being prescribed any drug versus a non-
prescription drug goes in the opposite direction if they arrive by ambulance. Meaning, if a 
patient arrives by ambulance, I would predict that they would be more likely to leave the 
ED with a non-prescription drug. This could indicate that the majority of patients that arrive 
by ambulance are in higher demand of non-prescription drugs. It is unclear why that is the 
case, but it is something worth considering in future research.  
This next variable looks at a patient that reports experiencing severe levels of pain 
(>5 on a 10-point scale). Similar to Outcome #1, patients that report these higher levels of 
pain are also more likely to receive a non-prescription drug. While the likelihood in this 
outcome is lower than Outcome #1’s results, it is still high overall as these patients are 
41 
1.608 times more likely to receive a non-prescription drug. It makes sense to me that 
patients that come in to the ED with high or severe levels of pain are more likely to receive 
some kind of drug intervention. I assume in most cases a patient presenting with high levels 
of pain likely leave the ED with a Tylenol or Motrin like drug. A patient that left a blank 
or unknown response to pain scale when they entered the ED do not appear to show any 
significant relationship to Outcome #2, similar to Outcome #1. 
Patients reporting heart/chest pain (not heartburn) are 1.686 times more likely to 
receive a non-prescription drug, compared to Outcome #1 where they are only 1.18 times 
more likely to receive any medication. This suggests the possibility that more patients with 
heart or chest pain symptoms have higher need of non-prescription drug means, or these 
non-prescriptions could be used in higher frequency for other reasons. Another possible 
reason for some patients could be they need surgery, not a medication. For patients 
reporting pain and fever, they are 1.744 times more likely to receive a non-prescription 
drug, similar to Outcome #1’s results of (1.776 times more likely). These results, along 
with Outcome #1’s, indicate symptom types do play a role in prescribing behaviors in 
whether a patient receives any medication and/or a non-prescription drug. 
d. Macro-Trends in Years for Outcome #2 (Non-prescription) 
The final observation worth analyzing from this table is the results shown in the 
prescribing patterns from 2012 to 2016. Similar to Outcome #1, 2012 is the omitted year 
group and there continues to be a trend that each subsequent year has a higher likelihood 
of a patient receiving a non-prescription drug. There are consistent increases from 2012 to 
2013, 2013 to 2014, then 2014 to 2015 where it drops slightly from 2015 to 2016 for all 
models except Model 4. Figure 4 reflects the increased likelihood of a non-prescription 
drug being prescribed for each year, and each model. 
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Figure 4. Outcome #2 Probability of Receiving a Non-prescription Drug 
Macro-Trend 2013–2016 (2012 is reference year) 
 
 
The trend for a patient receiving a non-prescription drug increases as seen in year 
2016 where a patient is 1.217-1.242 times more likely to receive a non-prescription drug. 
Outcome #1 and #2 both show an increased likelihood of a patient receiving a medication 
or a non-prescription drug, a consistent macro-trend in prescribing behaviors over time. 
3. Outcome #3 – Probability of an IV Given to Patient (IV) 
Table 8 presents the findings of the four models for my third and final Outcome #3 
(IV), assessing the likelihood of an IV being given to a patient. I expect the results for these 
models to vary from the first two outcomes, primarily due to the fact that a patient given 
an IV is a different intervention than receiving a medication or non-prescription drug like 
the first two outcomes.  
The key independent variable wait time (broken into quartiles) is statistically 
significant in all four models of this outcome. In all four models, longer wait time (when 
compared to the 1st quartile 0–8 minutes) is associated with lower likelihoods of an IV 
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being given to a patient. This may be due to the fact that patients that are in most need of 
an IV are seen immediately, possibly in the 1st quartile of wait time. This might explain 
why patients who wait longer have lower odds to be given an IV. The range of results for 
wait time reflects lower odds of being given an IV: by 12.5-19.7% in the 2nd quartile, by 
17.5-27.3% in the 3rd quartile, and by 19.6-29.2% in the 4th quartile; when compared to the 
1st quartile of wait time. I believe this reflects the nature of the patients’ symptoms as they 
enter the ED, and likely associated with the fact that patients in need of an IV may likely 
receive it immediately upon arrival, or at least more likely to receive it in the first 8 minutes. 
Table 8. Outcome #3: Logistic Regression (Odds Ratio) Probability 
of an IV Being Given 
Variable (Model 1) (Model 2) (Model 3) (Model 4) 
Wait Time (minutes)     
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Observations 98,451 98,451 98,451 98,451 
Note: Omitted reference groups include male, White, private insurance, and year 2012 for their 
respective categories. 
Exponentiated coefficients; Standard errors in parentheses 
* p < 0.05, ** p < 0.01, *** p < 0.001 
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a. Demographic Information Results for Outcome #3 (IV) 
The demographic information variables are discussed next for all three models on 
Outcome #3.  There appears to be mixed results across Model 2, 3, and 4 for the following 
demographic variables: age, female, Black, Race-Other, and Hispanic. The only variable 
in this outcome that shows no significant relationship to an IV being given is Asian.  
The age of a patient shows significance across Models 2, 3, and 4. The results 
indicate that as patients get older they are more likely to be given an IV. Even though 
Outcome #3 looks at a completely different outcome result (medication being given) I find 
it interesting that the odds ratios of age on Outcome #3 are higher than in Outcome #1.  
The indicator variable for female has higher odds of being given an IV in Models 
2, 3, and 4. This shows that female patients are 1.108-1.15 times more likely to receive an 
IV than males. These odds ratios are higher than those reported in Outcome #1 and 
Outcome #2 models, which is interesting because a female patient has a higher likelihood 
of being given an IV and a higher likelihood in some previous outcome models of receiving 
a medication or non-prescription drug. This is something I note in my recommendations 
section as an area of potential future research to understand why females tend to have 
higher visit rates to physicians, higher likelihoods of receiving a medication, and in some 
models higher likelihood of receiving a non-prescription drug. 
The next sub-category of variables I discuss are the race and ethnicity variables. 
The only race that shows no significance is Asian, the first outcome where Asian does not 
have a significant relationship in any of the models. For a patient that reported being Black, 
all three models have lower odds of being given an IV when compared to the reference 
group White (by 15.9-17.7%). Additionally, patients of other races have lower odds of 
being given an IV (by 11–13.2%) when compared to the reference group. Lastly, Hispanic 
patients are 1.08-1.113 times more likely to be given an IV during their visit to the ED. It 
is interesting to see that most race categories (when compared to the reference group) have 
lower odds to be given an IV, but the Hispanic ethnicity shows a higher likelihood of being 
given an IV. 
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b. Payment Method Results for Outcome #3 (IV) 
The payment method variables are discussed next for Models 3 and 4 on Outcome 
#3.  The results from these models show that patients that are self-pay, Medicare, Medicaid 
or CHIP, and pay-other have a statistically significant relationship with Outcome #3. There 
are a few interesting findings for payment method, the main one being that a Medicare 
patient is the only variable with an increased likelihood of being given an IV. Medicare 
patients are 1.1-1.139 times more likely to be given an IV when compared to a private 
insurance patient. This may be due to the average age, health, and condition of patients that 
are on Medicare versus private insurance. Either way, this is an interesting finding that 
could warrant future research, especially if patients of Medicare are experiencing above 
average demand for an IV. The remaining three significant variables (self-pay, Medicaid 
or CHIP, and pay-other) are discussed next. 
The interesting result for a self-pay patient from Models 3 and 4 shows this type of 
patient has lower odds of being given an IV when compared to a private insurance patient 
(by 17.8-18.4%). This means that a patient that pays for their healthcare needs out of their 
own pocket have lower odds to being given an IV than a patient with private insurance. 
The remaining two payment methods have nearly similar results as self-pay. Medicaid or 
CHIP and pay-other patients both have lower odds of being given an IV (by 15.4-19.3% 
and 15.4-17.6%, respectively), when compared to privately insured patients. It is 
interesting to see that only Medicare patients have a higher likelihood of being given an IV 
compared to the other groups. 
c. Clinical Characteristics Results for Outcome #3 (IV) 
The clinical characteristics variables are discussed next for Model 4 on Outcome 
#3.  The results from this model show the following variables to have a significant 
relationship to an IV being given: patient arrived by ambulance, experience severe pain 
(>5), heath/chest pain (not heartburn), and pain and fever symptoms. One thing to note is 
that the variable seen in the last 72 hours is not statistically significant like it is for Outcome 
#1 and #2. 
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A patient that arrived by ambulance is much more likely to be given an IV. In fact, 
they are 2.357 times more likely to be given an IV. This may not be too surprising 
considering most patients that arrive via an ambulance probably have a very serious issue, 
and most EMT’s are trained as a first step in triage to administer an IV when necessary. I 
assume the reason this variable has such a higher likelihood of a patient being given an IV 
is due to the fact that patients that arrive by ambulance are likely considered to be a higher 
risk and IV’s are given at least as a precautionary measure.  
A patient that claims severe levels of pain (>5 on a scale of 10) are only 1.041 times 
more likely to be given an IV. I would have thought this would have been higher, similar 
to those patients arriving by an ambulance, but it goes to show that even though a patient 
comes in with a high pain scale does not necessary mean they are highly likely to receive 
an IV. Lastly on pain scale, patients that left a blank or unknown response to pain scale 
when they entered the ED do not appear to show any significant relationship with Outcome 
#3. 
The next two variables are symptomatic behaviors of patients: those reporting 
heart/chest pain (not heartburn) and separately those reporting pain and fever. Both 
variables indicate a much higher likelihood of an IV being given. A patient reporting 
heart/chest pain (not heartburn) are 2.47 times more likely to be given an IV than a patient 
without such pain. For a patient reporting pain and fever, they are 2.799 times more likely 
to be given an IV. These are very interesting findings because they both hint toward 
possible triage procedures that could be in place for certain symptoms reported by patients, 
especially when they lead to higher likelihoods of an IV being given. 
d. Macro-Trends in Years for Outcome #3 (IV Fluids) 
The final observation worth analyzing from this table are the results shown in the 
prescribing patterns from 2012 to 2016. In the table, 2012 is the omitted year group, so all 
subsequent years show a decreased likelihood of an IV being given. This is in direct 
contrast to the trends we saw in Outcome #1 and #2, where there is a clear increase in 
prescribing behavior for ED visits. The results for Outcome #3 shows me that for every 
year after 2012, there is a lower likelihood of an IV being given. The range of values in 
48 
2013 lower odds (by 10.5-11%), in 2014 lower odds (by 7–9.1%), in 2015 lower odds (by 
14.4-15.8%), and lastly in 2016 lower odds (by 6.1-7.6%), when compared to 2012.  
Figure 5 reflects the macro-trend results. 
Figure 5. Outcome #3 Probability of an IV Given Macro-Trend 2013–2016 
(2012 is reference year) 
 
 
One possible explanation for the overall decreased likelihood of an IV being given 
to a patient could be associated with reimbursement rates. Meaning, lower fees paid by 
insurance providers could theoretically deter EDs from administering them as often. Recall 
that all payment methods had a lower likelihood of an IV being given, with the exception 
of Medicare. This is one possible explanation, but again something worth considering in 
future research. 
C. KEY FINDINGS 
In this sub-section, I summarize my key findings on wait time, then briefly touch 
on some interesting control variables that had an effect on the outcomes I analyzed.  
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The reason I am conducting this research is to understand the effects wait time has 
on my three outcome variables. In Outcome #1, Model 4 shows me the first sign that there 
is a statistically significant relationship for patients that have longer wait times. When a 
patient waited longer than 48 minutes to be seen they have lower odds of receiving a 
medication (by 6%) seen in Table 6. While this is encouraging, the four models done for 
Outcome #1 does not show overwhelming evidence of wait time affecting the likelihood 
of a patient being prescribed any medication. In Outcome #2, wait time shows more signs 
of having a significant relationship to receiving a non-prescription drug. This is true for all 
models at the 3rd quartile of time (21-47 minutes) where patients have lower odds of 
receiving a non-prescription drug (by 3.8-4.2%). This could be due to more serious patients 
having shorter wait times. 
The final outcome looked at is whether a patient has higher or lower odds to being 
given an IV (Outcome #3). In Outcome #3 wait time has a significant relationship in all 
four models when predicting the probability of a patient being given an IV. As patient wait 
time increases beyond the 1st quartile, the likelihood of getting an IV decreases in all four 
models. Clearly, Outcome #3 (IV) shows the most significant relationship with my key 
independent variable (wait time).  
Based on my literature review and results of my regressions, I agree that age does 
appear to have a significant relationship to increasing the likelihood of receiving a 
medication (Outcome #1). I also find a relationship exists between age and my other two 
outcome variables (Outcome #2 and #3). Sex, race, and ethnicity appear to have mixed 
effects based on the outcome variable being analyzed. The ones that stand out the most 
include Models 2 and 3 from Outcome #1 that show females are 1.091 times more likely 
and Asian patients have lower odds to receiving a medication (by 12.7-13%). Females are 
also up to 1.085 times more likely to receive a non-prescription drug in Outcome #2.  
As previously stated, an Asian patient has lower odds of receiving a medication in 
Outcome #1, but in Outcome #2 they are 1.148-1.189 times more likely to receive a non-
prescription drug. Also, a Hispanic patient has no relationship with Outcome #1, but shows 
a highly significant relationship in Outcome #2 where they are 1.0896-1.113 times more 
likely to receive a non-prescription drug. These results appear to indicate that both Asian 
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and Hispanic patients have a higher probability of visiting an ED for non-prescription drug 
needs. 
The next key finding looks at interesting takeaways from payment methods. A 
Medicare patient has a lower odd of receiving a medication in Model 3 Outcome #1 (by 
6.41%). Medicare patients also have lower odds by 4.9-5.8% to receive a non-prescription 
drug in Outcome #2, seen in Model 3 and 4. This is interesting because it may indicate the 
type of symptoms or reasons Medicare patients seek care in the ED if they are less likely 
to be seen for a medication or non-prescription drug. Conversely, Medicare patients are the 
only ones in Outcome #3 with a higher odd of being given an IV (1.1-1.139 times more 
likely) compared to a private insurance patient. Again, this finding is interesting due to the 
fact that Medicare is such a large government funded program and for some reason a 
Medicare patient has the highest odds of being given an IV. 
The clinical characteristics variables show the highest probabilities out of all the 
variables in my regressions. For example, in Outcome #1 patients experiencing severe pain 
are 2.168 times more likely to receive a medication, and patients with pain and fever 
symptoms are 1.776 times more likely. In Outcome #2 these two variables are still good 
indicators of increasing the likelihood of receiving a non-prescription drug, but so is heart 
and chest pain (not heartburn) who are 1.686 times more likely. Lastly, for Outcome #3 the 
variables that stood out the most include: whether the patient arrived by ambulance, 
patients with heart/chest pain, and those with pain and fever symptoms; all of which are 
twice as likely to be given an IV (2.357, 2.47, and 2.799 times more likely, respectively). 
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V. CONCLUSION AND RECOMMENDATIONS 
A. CONCLUSION 
I started this research project based on personal experiences I have had, both in the 
military and civilian healthcare systems. I have experienced long wait times myself, and 
witnessed EDs on multiple occasions that appeared under-staffed and overworked. I use 
the NHAMCS data to analyze my key indicator variable of wait time and find some 
interesting key findings as seen in Chapter IV. I am able to find models and outcomes that 
indicate when wait time increases and decreases the likelihood of an outcome (e.g., patient 
receiving a medication, receiving a non-prescription drug, or being given an IV). I also 
identify macro-trends in ED drug prescribing rates that have increased over the years, and 
a pattern of decreasing likelihood of an IV being given over that same time period.  
In my thesis, my goal includes finding answers the to the following questions. 
1. Is there an association between patient wait time and probability of 
receiving medication? 
2. What are the other determinants of the medication outcomes? 
3. What are the macro-trends over the five years of data of the medication 
outcomes? 
My research evolved from just analyzing wait time against Outcome #1 
(medications) to a more robust analysis on the odds of a patient receiving a non-
prescription drug (Outcome #2) and the odds of an IV being given (Outcome #3). The 
findings for my three outcomes and the four models I use within each, suggest there are 
multiple variables with significant relationships to each respective outcome. These findings 
have the ability to aid and educate healthcare professionals in understanding how 
demographic information, patient payment method, and clinical characteristics affect the 
probability of a patient receiving a medication, a non-prescription drug, and/or being given 
an IV. My hope is that these same healthcare professionals can extrapolate results from my 
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study pertinent to their area of expertise and find new workflow efficiencies or cost-saving 
initiatives that can positively influence the healthcare community. 
With regard to Outcome #1 (probability of receiving a medication) the data shows 
that patients who wait longer than 48 minutes (4th quartile) have lower odds to receiving a 
medication. I also find age, female, Black, and Race-Other patients have an increased 
likelihood of being prescribed a medication whereas Asian patients have a decreased 
likelihood in various models for this outcome. When looking at a patient’s payment 
method, those who are self-pay have an increased likelihood of being prescribed a 
medication whereas those in the pay-other variable have a decreased likelihood. In the 
clinical characteristics section, a patient experiencing severe pain, with symptoms of 
heart/chest pain (not heartburn), or pain and fever symptoms are all more likely to be 
prescribed a medication. Conversely, a patient seen in the last 72 hours, or if they arrived 
by an ambulance, have lower odds to receiving a medication.  
With regard to Outcome #2 (probability of receiving a non-prescription drug) 
patients in the 3rd quartile of time (21-47 minutes) show a decreased likelihood of receiving 
a non-prescription drug in all four models. In Model 4 the 3rd quartile of wait time shows 
lower odds of receiving a non-prescription drug. I also find age, female, Asian, Race-Other, 
and Hispanic patients have an increased likelihood of receiving a non-prescription drug. 
When looking at a patient’s payment method, a Medicare patient is the only significant 
relationship in this outcome and they show a decreased likelihood of receiving a non-
prescription drug when compared to a private insurance patient. In the clinical 
characteristics section, a patient that arrived by ambulance, experiences severe pain, has 
symptoms of heart/chest pain (not heartburn), or symptoms of pain and fever are all more 
likely to receive a non-prescription drug. Conversely, a patient seen in the last 72 hours has 
lower odds to receiving a non-prescription drug.  
With regard to Outcome #3 (probability of an IV being given) patients in the 2nd, 
3rd, and 4th quartiles of wait time all show a decreased probability of being given an IV. I 
also find age, female, and Hispanic patients have an increased likelihood of being given an 
IV. Conversely, a Black or a Race-Other patient have lower odds of being given an IV. In 
payment methods a Medicare patient is the only one with an increased likelihood of being 
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given an IV whereas self-pay, Medicaid or CHIP, and other-pay are all less likely to be 
given an IV. In the clinical characteristics section, a patient that arrives by ambulance, 
experiences severe pain, has symptoms of heart/chest pain (not heartburn), or symptoms of 
pain and fever are all more likely to be given an IV.  
B. RECOMMENDATIONS 
Moving forward, I recommend researchers take my results and identify a finding 
that is applicable to their situation and research it further. I find the results of wait time to 
be most interesting in Outcome #3 due to the decreased likelihood of an IV being given, 
and with all three quartiles being statistically significant in that outcome. In all three 
outcomes I also find that clinical characteristics have the largest effects, a finding that is 
also worth nothing for potential future research. I list some specific recommendations from 
my other findings below.  
1. Follow-up on the macro-trends seen in 2012–2016 with more recent years of 
data to see if the trend is still increasing. In my analysis it is evident that prescribing 
behaviors for medication and non-prescription drugs has increased from 2012 through 
2016. Future research can look further into why this is true for the years I have analyzed, 
or continue by researching the most recent three-to-five years of data available to see if the 
trend is still present. I also recommend looking further into the probability of an IV being 
given, which shows a decreased likelihood in the macro-trend analysis over the years. 
Contrary to the results of higher prescribing patters of medications, I find that over time 
IV’s are not as likely to be given. I make the assumption that the reason could possibly be 
related to reimbursement rates, but that would mean providers are either more or less 
critical in their assessments of a patients need for an IV. It is unclear in my analysis why 
this trend appears to be decreasing, but I do hope it is due to medical providers being more 
efficient and accurate in assessing when a patient actually needs an IV vs being driven by 
things like reimbursement rates (regardless of necessity). 
2. In my analysis female patients have a higher likelihood in all three of my 
outcomes, but why?  I believe the findings for female patients warrants future research 
and analysis based on multiple findings in my research. In the literature review, I point out 
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the fact that females have higher visit rates to physicians than males. In my data I am able 
to show that females also have a higher likelihood of receiving a medication and non-
prescription drug, as well as having a higher likelihood of being given an IV. Once I control 
for pain experiences in Model 4, the higher likelihood of female receiving medication 
disappear for Outcome #1, but not in Outcome #2. I find these results very intriguing and 
worth future research and analysis. If this trend continues, I believe there is a possibility to 
better understand the drivers to see if there are alternative methods to better meet the 
healthcare needs of a female patient. For example, e-visits could be more widely available 
for certain female related medical visits which would decrease demand for a face-to-face 
visit. This is just one example idea worth pursuing in future research targeted towards 
understanding these findings for a female patient in my study. 
3. Continue further research in clinical characteristics such as ambulance 
arrival, pain scale, and symptoms to better understand patients as they arrive. This 
type of continued research has the potential to aid in triage methodologies or projecting 
manpower needs.  In more than one outcome my data shows how variables such as 
ambulance arrival, patients experiencing severe pain, symptoms of heart/chest pain or pain 
and fever can all significantly increase the likelihood of a patient receiving a medication or 
being given an IV. My research just scratched the surface on types of symptoms that could 
be looked at, but these findings do suggest that healthcare professionals can capture this 
type of data prior to treatment and potentially plan for a plan of care based on probabilities. 
I make this statement in general terms as I understand every patient is different. But, I 
believe healthcare professionals can use these types of findings to analyze their own patient 
database, see the most recurring clinical characteristics, find trends in hours, days, weeks, 
or months that these characteristics ebb and flow, then apply workflow or manpower 
solutions appropriately.  
Given the findings throughout my thesis, I believe follow on research could warrant 
relevant results for the medical community to consider. I have listed some example 
recommendations above, but my hope is that the healthcare community continually strives 
to understand its patients through analysis of variables such as demographic information, 
payment method, and clinical characteristics. I have shown in my analysis that these types 
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of variables do in fact have significant relationships with predicting outcomes such as the 
likelihood of a patient receiving medication or being given an IV. My findings have the 
potential to aid in the following: establish new and more efficient triage of procedures, 
build awareness within the healthcare community on variables that are driving higher 
prescription rates, and creating manpower plans based on localized data. The healthcare 
industry is faced with daunting challenges in the future. The United States healthcare 
system improves with every small step taken towards advancing work flow efficiencies, 
cutting waste, and improving the overall quality of care. I hope that the results of my thesis 
play a role in influencing one such small step. 
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